Bode C, Gulba D, Huber K, Runge M S
Department of Cardiology, Medical Clinic III, University of Heidelberg, Germany.
Ann Hematol. 1996;73 Suppl 1:S1-7.
Large efforts have been undertaken to develop more effective and safer thrombolytic agents than those currently used in clinical practice. In addition, the value of adjunctive agents influencing thrombotic and thrombolytic processes could be shown and newer agents are under active investigation. This review focuses on theoretical and practical aspects of optimizing thrombolytic therapy and mainly on genetically engineered, third generation plasminogen activators. Optimized thrombolytic therapy may make this form of therapy available to patients that are currently considered ineligible and it may lead to earlier, more complete reperfusion of infarct related coronary arteries. The benefits and risks of optimized thrombolytic regimens relative to mechanical reperfusion strategies will have to be constantly reassessed as both forms of treatment develop.
人们已付出巨大努力来研发比目前临床实践中使用的溶栓剂更有效、更安全的药物。此外，已证实辅助药物对血栓形成和溶栓过程有影响，新型药物正在积极研究中。本综述重点关注优化溶栓治疗的理论和实践方面，主要是基因工程第三代纤溶酶原激活剂。优化的溶栓治疗可能使目前被认为不符合条件的患者也能接受这种治疗方式，并可能使梗死相关冠状动脉更早、更完全地再灌注。随着两种治疗方式的发展，必须不断重新评估优化溶栓方案相对于机械再灌注策略的益处和风险。
